COMEM NATURAL JSC: GLP-1 import refusal records
Has FDA refused imports of GLP-1 products from COMEM NATURAL JSC?
Yes. FDA’s import refusal records list 3 refused shipment lines declared as made by COMEM NATURAL JSC (Vietnam) whose FDA product code names retatrutide, on Sep 24, 2026. None of them carries a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.
- Country
- Vietnam
- City in FDA records
- Ha Noi
- FEI numbers on the lines
- 3044410908
- Refused lines
- 3
- Lines with an Import Alert 66-80 API or powder code
- 0
- Drugs named in the product codes
- Retatrutide
- Refusal dates
- Sep 24, 2026
The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.
Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether COMEM NATURAL JSC is on it.
Refused shipment lines
| FDA refusal charges | Shipment ID | ||||
|---|---|---|---|---|---|
| Sep 24, 2026 | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 1FX-2060079-8/20002/1D |
| Sep 24, 2026 | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 1FX-2060079-8/20002/1H |
| Sep 24, 2026 | Vietnam | 61PDZ78 RETATRUTIDE (ANTI-DIABETIC) | Code not listed on Import Alert 66-80 | 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 1FX-2060079-8/20002/1I |
FDA refusal charges on these lines
A line can carry several charges. Text is FDA’s charge statement, verbatim.
| 708NOREG A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug and appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act. | 3 |
| 708LIST A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears to not be included in a list required by section 510(j). | 3 |
| 708LBLFR A: The article is subject to refusal of admission and administrative destruction pursuant to section 801(a)(3) of the FD&C Act in that it is a drug, and it appears in a package form to not bear a label containing the name and place of business of the manufacturer, packer, or distributor. | 3 |
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
Records last pulled Nov 15, 2026. Every entry links to the original public record.
3 lines from FDA files read Nov 15, 2026.